The remake will feature a number of changes including the addition of a lesbian couple at the centre of the plot The post BFI ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

The Gladstone Institutes is comprised of three institutes in the San Francisco area which began in 1979. The Gladstone Institute of Cardiovascular Disease focuses on atherosclerosis and its ...

If shaving is growing tiresome, consider laser hair removal: This method damages hair follicles to reduce growth over time, ultimately giving more long-term results than using a razor. After ...

Katy is an avid beauty buff with extensive personal experience serving as an eager tester of brands large and small, drugstore and luxury, on behalf of family and friends alike. She's a Columbia ...

Pubic hair, a surprisingly controversial topic, is having a moment thanks to a growing TikTok trend that all started with…an Etsy review. Stay with me here. TikToker @sujindah went viral for a ...

OnlyFans stars Lilly Phillips and Bonnie Blue are vying to have sex with more men, a feud that drove social media crazy back in 2024, when Phillips met the challenge of sleeping with 100 men in 24 ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Lilly plans to share its full Q4 2024 results on 6 February 2025. Credit: JHVEPhoto via Getty Images. Eli Lilly has announced a $400m reduction in its 2024 revenue forecast, marking a 3% shortfall ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations. The ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...